´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2023-03-10±³À°ÀÏÀÚ : 2023-03-10
±³À°Àå¼Ò : ¼¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽÇ
±³À°ÁÖÁ¦ :
´ëÇÑ¿ì¿ïÁ¶¿ïº´ÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑ¿ì¿ï.Á¶¿ïº´ÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : ¿ì¿µ¼·
¿¬¶ôó : 02-3779-1250
À̸ÞÀÏ :
webmaster@theksad.or.kr ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 90,000¿ø
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø 6¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø, ºñȸ¿ø 7¸¸¿ø, Æò»ýȸ¿ø ¸éÁ¦ ´çÀϵî·Ï: Á¤È¸¿ø 8¸¸¿ø, ÁØȸ¿ø 6¸¸¿ø, ºñȸ¿ø 9¸¸¿ø, Æò»ýȸ¿ø 1¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 09:30~09:50 Sleep disorders ±è³«¿µ(°è¿äº´¿ø)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 09:50~10:10 Attention Deficit Hyperactivity Disorder(ADHD) ÃÖ¿ø¼®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 10:10~10:30 Anxiety disorders ¼Û¹Î±Ô(¼º¸ð°ø°¨Á¤½Å°Ç°ÀÇÇаúÀÇ¿ø)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 10:30~10:45 Neurocognitive disorders ½Åö¹Î(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 11:00~11:25 Childhood trauma in mood disorders °ÇÑ°íÀººñ(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 11:25~11:50 Neurobiological mechanisms of childhood trauma ±è½Â°ï(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 11:50~12:10 Childhood trauma and treatment of mood disorders ±èÁö¼±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 12:10~12:40 Why is it important to prevent recurrence of this disease? ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 12:40~13:10 Improving patient-centered outcome of bipolar disorder with long-acting-injectable antipsychotics Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 13:30~13:55 Definition and epidemiology of Treatment-resistant depression(TRD) ¼ºÇü¸ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 13:55~14:20 Neurobiology of Treatment-resistant depression(TRD) ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 14:20~14:40 Treatment of Treatment-resistant depression(TRD) ¿ì¿µ¼·(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 14:40~15:10 Brilliant efficacy of Vortioxetine on mood and cognitive function Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 15:10~15:40 Unique efficacy of Vortioxetine on emotional blunting and anhedonia ÀüÈ«ÁØ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 15:50~16:05 In children and adolescents À̹®¼ö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 16:05~16:20 In elderly people ±èÅÂÈñ(¿¬¼¼¿øÁÖÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 16:20~16:35 In women ¿ÀÈ«¼®(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 03-10 ÄÁº¥¼ÇȦ 16:35~17:00 In traumatized people ±è¿øÇü(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 09:30~09:55 Functional connectivity ³ª°æ¼¼(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 09:55~10:20 Polygenic risk score ¹Ú¼º¿ë(°è¿äº´¿ø)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 10:20~10:45 Functional Near Infrared Spectroscopy(fNIRS) ¾çÂù¸ð(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 11:00~11:25 Concept and diagnosis ÀÓÀº¼º(½Å¼¼°èÈ¿º´¿ø)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 11:25~11:50 Comorbidity and course È«Á¤¿Ï(Àͻ꺴¿ø)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 11:50~12:10 Treatment ¹è½Â¹Î(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 12:10~12:40 Management of major depressive disorder in COVID-19 era õÀºÁø(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 12:40~13:10 The clinical overview/implications of Desvenlafaxine as the 1st line treatment in diverse Major Depressive Disorder(MDD) patients ÀÌ°¼ö(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 13:30~14:40 Psychological Intervention for Complicated Grief ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 14:40~15:10 Pharmacological approach for optimal treatment of bipolar disorders ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 15:10~15:40 Olanzapine ±è¼±¹Ì(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 15:50~16:15 Is the monoamine theory a fiction? ±è°æ¹Î(±¹¸³³ªÁÖº´¿ø)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 16:15~16:40 Neurocircuit theory ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-10 ´ëȸÀÇ½Ç 16:40~17:00 Neurogenesis theory À±¼®È£(¿µ³²ÀÇ´ë)